Stock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects

Stock Track

2024-11-18

Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.

Goldman Sachs upgraded Autolus Therapeutics to a "Buy" rating from "Neutral" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.

Additionally, analysts polled by Capital IQ have an average "Buy" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1148503177"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148503177\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1148503177?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148503177","market":"hk","top_or_hot":-1,"title":"Stock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects","media":"Stock Track","content":"<p>Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.</p>\n\n<p>Goldman Sachs upgraded Autolus Therapeutics to a \"Buy\" rating from \"Neutral\" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.</p>\n\n<p>Additionally, analysts polled by Capital IQ have an average \"Buy\" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-18 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.</p>\n\n<p>Goldman Sachs upgraded Autolus Therapeutics to a \"Buy\" rating from \"Neutral\" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.</p>\n\n<p>Additionally, analysts polled by Capital IQ have an average \"Buy\" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUTL","symbol_name":"Autolus Therapeutics PLC","start_time":0,"source_url":"","article_id":"1148503177","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148503177","pubTimestamp":1731934934,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Autolus Therapeutics PLC  saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.Goldman Sachs upgraded Autolus Therapeutics to a \"Buy\" rating from \"Neutral\" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUTL":"Autolus Therapeutics PLC"},"translate_title":"由于分析师升级和FDA批准前景，股票跟踪Autolus Therapeutics盘前飙升9.7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUTL":1},"content_text":"Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.\nGoldman Sachs upgraded Autolus Therapeutics to a \"Buy\" rating from \"Neutral\" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.\nAdditionally, analysts polled by Capital IQ have an average \"Buy\" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}